Lipocine vs Praxis Precision Medicines
LPCN and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and PRAX compare
Praxis Precision Medicines is the larger company, worth 650 times as much as Lipocine ($9.2B against $14.1M).
Lipocine scores higher on the StockData Score (11 against 7 for Praxis Precision Medicines), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | PRAX |
|---|---|---|
| Size and price | ||
| Market cap | $14.1M | $9.2B |
| Share price | $1.71 | $328.13 |
| Change, 1 year | −41.4% | 78.7% |
| Change, 5 years | −91.4% | 17.2% |
| Beta (5Y) | 0.66 | 1.65 |
| Employees | 14 | 168 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× | – |
| P/B | 0.7× (better) | 7.3× |
| FCF yield | – | −3.5% |
| Fair value | $3.29 | – |
| Margin of safety | 48.0% | – |
| Growth | ||
| Revenue growth (TTM) | −13.4% | – |
| Profitability | ||
| Operating margin | −269% | – |
| Net margin | −249% | – |
| Return on equity | −52.9% | −44.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.36 | 14.53 (better) |
| Altman Z-score | −9.08 | 102.83 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −114% | – |
| Shareholder yield | −114% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 121% |
| Held by insiders | 8.4% | 0.72% |
| Insider net buying, 12 months | $517K (better) | −$3.6M |
| Short interest, % of float | 4.3% | 15.2% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- PRAX stock overview
- PRAX income statement
- PRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.